These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. Ettrup A; Palner M; Gillings N; Santini MA; Hansen M; Kornum BR; Rasmussen LK; Någren K; Madsen J; Begtrup M; Knudsen GM J Nucl Med; 2010 Nov; 51(11):1763-70. PubMed ID: 20956470 [TBL] [Abstract][Full Text] [Related]
6. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
7. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Ettrup A; Hansen M; Santini MA; Paine J; Gillings N; Palner M; Lehel S; Herth MM; Madsen J; Kristensen J; Begtrup M; Knudsen GM Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):681-93. PubMed ID: 21174090 [TBL] [Abstract][Full Text] [Related]
9. The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Jalal B Psychopharmacology (Berl); 2018 Nov; 235(11):3083-3091. PubMed ID: 30288594 [TBL] [Abstract][Full Text] [Related]
10. Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain. Finnema SJ; Stepanov V; Ettrup A; Nakao R; Amini N; Svedberg M; Lehmann C; Hansen M; Knudsen GM; Halldin C Neuroimage; 2014 Jan; 84():342-53. PubMed ID: 23994452 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. Stahl SM CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570 [TBL] [Abstract][Full Text] [Related]
12. Serotonin 2A receptor agonist binding in the human brain with [(11)C]Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [(18)F]altanserin. Ettrup A; Svarer C; McMahon B; da Cunha-Bang S; Lehel S; Møller K; Dyssegaard A; Ganz M; Beliveau V; Jørgensen LM; Gillings N; Knudsen GM Neuroimage; 2016 Apr; 130():167-174. PubMed ID: 26876490 [TBL] [Abstract][Full Text] [Related]